A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers.
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms MIURCCEVERO
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Oct 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
- 12 Oct 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.